
Shionogi Inc. announced it has completed its $2 billion acquisition of IntraBio Inc., the Texas-based biotech behind AQNEURSA, a treatment for a handful of rare and devastating neurological disorders. The deal closed on November 18, folding IntraBio into Shionogi as a wholly owned subsidiary and handing the Japanese pharmaceutical company full control of a drug that patient advocacy groups have described as transformative for the families who rely on it.
Shionogi first announced its agreement to acquire IntraBio on October 5, and under the terms of that deal, Shionogi Inc. paid a lump sum of $2.0 billion to acquire all outstanding shares of IntraBio, according to Shionogi. The payment covers global intellectual-property and commercialization rights to AQNEURSA, also known by its generic name levacetylleucine. Founded in 2015, Texas-based IntraBio is now a wholly owned subsidiary of Shionogi Inc., as reported by NJBIZ.
AQNEURSA treats rare neurological disorders including Niemann-Pick disease type C, and the drug received FDA approval in 2024. Shionogi's statement notes the drug was approved by the U.S. Food and Drug Administration in 2024 and by the European Medicines Agency in January 2026 for the neurological manifestations of that disease. The company's announcement carries added weight given the drug's rapid expansion into a second rare condition just months before the acquisition closed.
A Second FDA Approval Widens the Drug's Reach
In September 2026, the FDA approved AQNEURSA as the first and only treatment option for ataxia in adults and pediatric patients with ataxia-telangiectasia, a rare genetic condition affecting the nervous system, immune system and other body systems, per Cleveland Clinic. The drug is also currently under review by the EMA for adult and pediatric patients diagnosed with A-T. Beyond that, AQNEURSA is being studied in a Phase III, randomized, placebo-controlled, double-blind, crossover study to treat CACNA1A neurological and neurodevelopmental disorders, the company's announcement states.
Patient advocacy organizations welcomed the deal. The A-T Children's Project and the National Niemann-Pick Disease Foundation both applauded Shionogi's acquisition, according to the company statement. Brad Margus said the U.S. approval of AQNEURSA for ataxia-telangiectasia has brought new hope to children and families affected by the disease, and he added that he hopes Shionogi's reach and resources will help more families access the treatment.
Executives Frame the Deal as Rare-Disease Strategy
Isao Teshirogi said Shionogi welcomes AQNEURSA and gains rare-disease expertise and global capabilities through the acquisition. Nathan McCutcheon, Shionogi's subsidiary president and CEO, told NJBIZ that through acquisitions, integrations and strategic hires, Shionogi is building a strong, sustainable rare disease presence. The company's statement adds that Shionogi will continue programs initiated by IntraBio and explore further research opportunities for AQNEURSA in rare diseases.
The purchase also brings Shionogi a broader pipeline. IntraBio's clinical programs extend beyond AQNEURSA's approved uses into Pompe disease, Fragile X syndrome and Jordan's syndrome, giving the subsidiary several additional avenues for future rare-disease development. Financially, IntraBio reported sales of $68 million in 2025, Shionogi said, according to BioPharma Dive.
Part of a Bigger Rare-Disease Buildout
The IntraBio purchase follows another major rare-disease move earlier this year. In April 2026, Shionogi obtained rights to the ALS treatments Radicava ORS and IV Radicava in a deal NJBIZ described as worth $2.5 billion, bringing amyotrophic lateral sclerosis medications into the company's portfolio. Shionogi has said that since acquiring the global rights to edaravone in April 2026, it established a strong commercial foundation in rare disease — a foundation the IntraBio purchase now builds upon.
Shionogi & Co. Ltd. is headquartered in Japan, while its U.S. subsidiary Shionogi Inc. is based in Florham Park, New Jersey. With AQNEURSA's expanding approvals and IntraBio's additional pipeline now under one roof, the company appears positioned to keep pursuing rare-disease acquisitions as a core part of its growth strategy.









